Protein kinase A (PKA)--a potential target for therapeutic intervention of dysfunctional immune cells.
Curr Drug Targets
; 6(6): 655-64, 2005 Sep.
Article
en En
| MEDLINE
| ID: mdl-16178799
ABSTRACT
In several cases of immunodeficiency and autoimmunity, the dysfunctional immune system is associated with either hypo- or hyperactive T and B cells. In autoimmune conditions such as systemic lupus erythematosus (SLE) and immunodeficiencies such as acquired immunodeficiency syndrome (AIDS), it has been demonstrated that the regulatory effect of the signaling pathway of cyclic 3', 5' adenosine monophosphate (cAMP) and cAMP-dependent protein kinase (PKA) is abrogated. PKA is well-known as a key regulator of immune responses in that it inhibits both early and late phases of antigen induced T and B cell activation. Here we will discuss a potential useful strategy for therapeutic interventions of dysfunctional T cells associated with SLE and HIV by modulation of the cAMP-PKA pathway. Therefore, we will describe the components and architecture of the cAMP-PKA signaling pathway in T cells in order to point out one or several steps which potentially may serve as targets for therapeutic intervention.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Activación de Linfocitos
/
Linfocitos T
/
Infecciones por VIH
/
Proteínas Quinasas Dependientes de AMP Cíclico
/
Lupus Eritematoso Sistémico
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Drug Targets
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2005
Tipo del documento:
Article
País de afiliación:
Noruega